Recent Securities Litigations

BioMarin Pharmaceutical Inc. Common Stock (NASDAQ: BMRN)

Company Name:BioMarin Pharmaceutical Inc. Common Stock
Stock Symbol:NASDAQ: BMRN
Class Period Start:11/14/2019
Class Period End (inclusive):02/23/2022

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) BMN 307 was less safe than BioMarin had led investors to believe; (ii) BMN 307's safety profile made it likely that the FDA would place a clinical hold on the Phearless Phase 1/2 study; (iii) accordingly, the Company had overstated BMN 307's clinical and commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.